Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multi-Centre, Randomized Controlled Trial to Assess the Safety and Effectiveness of the Vaginal Microbicide 1% Tenofovir Gel in the Prevention of Human Immunodeficiency Virus Type 1 Infection in Women, and to Examine Effects of the Microbicide on the Incidence of Herpes Simplex Virus Type 2 Infection

NCT01386294 is registered in ClinicalTrials.gov with CONRAD as lead sponsor.

NCT NCT01386294
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01386294 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multi-Centre, Randomized Controlled Trial to Assess the Safety and Effectiveness of the Vaginal Microbicide 1% Tenofovir Gel in the Prevention of Human Immunodeficiency Virus Type 1 Infection in Women, and to Examine Effects of the Microbicide on the Incidence of Herpes Simplex Virus Type 2 Infection
Lead sponsor
CONRAD
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2011
Completion date
August 31, 2014
Enrollment
2,059 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

hiv prevention